Huperzine A (Lycopodium Alkaloid · AChE Inhibitor · Cognitive Enhancement)

Compound	Huperzine A
Chemical class	Alkaloid — Lycopodium (Sesquiterpene Alkaloid)
CAS	102518-79-6
Primary source	Huperzia serrata (toothed club moss), Lycopodium spp.
Key applications	Cognitive enhancement, AChE inhibition, Alzheimer support, neuroprotective
Claim strength	Moderate
Typical form	Huperzine A 98% isolate; Huperzia serrata 1% extract
Buy from Herbuno	Huperzine A 98% Extract Powder | Standardized Huperzia serrata →

Commercial source: Huperzine A is commercially available as a high-purity isolate (98% HPLC) and as a standardised Huperzia serrata (toothed club moss) extract at 1% huperzine A. See sourcing options below. Traditional use: Huperzia serrata (Qian Ceng Ta in TCM) has been used in Chinese traditional medicine for centuries for fever, inflammation, blood disorders, and memory complaints. The specific AChE-inhibiting mechanism was not understood traditionally, but the cognitive-enhancing properties were empirically recognised. Modern isolation of huperzine A in the 1980s by Chinese scientists established the pharmacological basis for these traditional uses. Research trajectory: Huperzine A has one of the strongest evidence bases for cognitive enhancement among botanical alkaloids. Multiple Chinese RCTs demonstrate significant improvements in cognitive function in Alzheimer’s disease patients. It is a reversible, selective AChE inhibitor with superior CNS penetration and longer duration of action compared to pharmaceutical AChE inhibitors (donepezil, rivastigmine). See sourcing options below.

---

Evidence for Huperzine A Applications

Alzheimer’s disease — AChE inhibition: Multiple Chinese RCTs (including 3 meta-analyses) demonstrate huperzine A (100–400 µg/day) significantly improves cognitive function, ADL scores, and memory performance in mild-to-moderate Alzheimer’s disease patients. Huperzine A is a reversible, highly selective AChE inhibitor that crosses the blood-brain barrier effectively and has a longer duration of action than donepezil. A Cochrane review noted positive evidence but called for larger Western RCTs. Claim strength: Moderate (multiple Chinese RCTs; limited independent Western replication).

Healthy adult cognitive performance: Small human studies in healthy adults show improvements in working memory, attention, and learning speed with huperzine A (100 µg twice daily). Chinese adolescent memory improvement studies showed significant benefits in academic performance. Relevant for cognitive enhancement supplement positioning in healthy populations. Claim strength: Moderate.

Neuroprotective beyond AChE: Huperzine A activates Nrf2/HO-1, protects against glutamate-induced excitotoxicity (NMDA receptor modulation), reduces amyloid-beta production, and has anti-apoptotic effects — neuroprotective mechanisms beyond simple AChE inhibition that distinguish it from purely symptomatic pharmaceutical AChE inhibitors. Claim strength: Moderate.

---

Dosage & Formulator Specification

Clinical dose range: 100–400 µg (micrograms) per day huperzine A — note microgram not milligram dosing. For Herbuno’s Huperzine A 98% isolate: 0.1–0.4 mg/day; for the Huperzia serrata 1% extract: 10–40 mg/day extract delivers 0.1–0.4 mg huperzine A. Divided dosing (twice daily) is standard in clinical studies. The very low active dose means precise weighing and blending is essential — Huperzine A 98% must be blended with a diluent/carrier for accurate dosing in commercial formulations.

Huperzine A 98% from Herbuno is the highest-purity commercial form, enabling precise microgram-level dose control. Specify huperzine A content in micrograms per serving on the finished product label — this is the clinically meaningful unit. Stability: huperzine A is relatively stable in dry powder formulations; light and moisture sensitive. Standard opaque packaging is adequate; no refrigeration required.

Drug interaction consideration: huperzine A inhibits AChE and may interact with anticholinesterase drugs (pharmaceutical AChE inhibitors for Alzheimer’s — donepezil, rivastigmine, galantamine) causing additive cholinergic effects. Co-administration with pharmaceutical AChE inhibitors should be disclosed to the prescribing physician. Not recommended alongside cholinergic drugs without medical supervision.

---

Frequently Asked Questions — Huperzine A

Is huperzine A better than pharmaceutical AChE inhibitors for Alzheimer’s?
Huperzine A has comparable AChE inhibitory potency to donepezil in vitro, with superior CNS selectivity and longer duration of action. Head-to-head Chinese clinical trials are limited. Huperzine A has additional neuroprotective mechanisms (Nrf2, NMDA modulation, amyloid reduction) not present in purely AChE-inhibitory drugs. For clinical Alzheimer’s management in most Western markets, pharmaceutical AChE inhibitors remain the standard of care. Huperzine A is a clinically rational supplement for cognitive support and mild impairment positioning.

What is the correct dose unit for huperzine A — micrograms or milligrams?
Micrograms (µg). This is critical. Clinical doses are 100–400 µg/day — not milligrams. Milligram-level dosing would represent 1000-fold overdosing with severe cholinergic toxicity risk. Many supplement label errors involving huperzine A relate to incorrect dose unit declaration. Always verify: 200 µg = 0.2 mg = 200 micrograms. Include both microgram and milligram values on labels to reduce misinterpretation.

Is huperzine A safe for daily long-term use?
Clinical trials of up to 6 months show acceptable tolerability. Adverse effects at clinical doses are mild cholinergic — nausea, sweating, bradycardia at higher doses. Some practitioners recommend cycling (e.g., 5 days on, 2 days off) to prevent AChE downregulation, though this is precautionary rather than evidence-based. Long-term safety beyond 6 months in continuous use is not well-characterised. Include advisory language for individuals with cardiovascular conditions (bradycardia risk) and cholinergic-sensitive populations.

Does huperzine A from Huperzia serrata differ from synthetic huperzine A?
Chemically identical. Natural huperzine A from Huperzia serrata extraction and synthetic huperzine A (chemical synthesis) are the same molecule. Many commercial huperzine A preparations are semi-synthetic (produced via chemical modification of naturally-extracted precursors) or synthetic. For “natural” labelling, the Huperzia serrata-derived extract (1% huperzine A) is appropriate. Herbuno’s 98% isolate requires botanical source confirmation to support natural source labelling.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery